Exagen Inc. (NASDAQ:XGN) is a company that focuses on the development and commercialization of diagnostic tests for autoimmune diseases. The company aims to improve patient care by providing accurate and timely diagnostic information. In the competitive landscape, Exagen faces competition from other biotech firms like TELA Bio, Phathom Pharmaceuticals, IGM Biosciences, and Centogene.
Exagen's Return on Invested Capital (ROIC) is -27.88%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 11.12%. This negative ROIC indicates that Exagen is not generating sufficient returns to cover its cost of capital, highlighting inefficiencies in its capital utilization.
In comparison, TELA Bio has an even lower ROIC of -71.13% against a WACC of 10.24%, resulting in a ROIC to WACC ratio of -6.95. This suggests that TELA Bio is facing greater challenges in capital efficiency compared to Exagen.
Phathom Pharmaceuticals shows a ROIC of -149.31% with a WACC of 8.86%, leading to a ROIC to WACC ratio of -16.86. This is the most negative among the peers, indicating significant inefficiencies in generating returns relative to its cost of capital.
IGM Biosciences and Centogene also report negative ROICs of -27.60% and -48.34%, respectively. Their WACC figures are 5.54% and 9.72%, resulting in ROIC to WACC ratios of -4.98 and -4.97. Among the peers, Centogene has the least negative ratio, suggesting slightly better capital utilization despite still operating at a loss.
